Insider Selling: Cerus Co. (NASDAQ:CERS) CFO Sells 23,147 Shares of Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 23,147 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $1.45, for a total transaction of $33,563.15. Following the transaction, the chief financial officer now owns 912,607 shares in the company, valued at approximately $1,323,280.15. This trade represents a 2.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 7th, Kevin Dennis Green sold 31,148 shares of Cerus stock. The shares were sold at an average price of $1.50, for a total value of $46,722.00.
• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The shares were sold at an average price of $1.58, for a total value of $95,836.48.

Cerus Stock Performance

NASDAQ CERS remained flat at $1.45 during trading hours on Monday. The company had a trading volume of 1,979,196 shares, compared to its average volume of 1,302,541. The company’s 50-day moving average is $1.72 and its two-hundred day moving average is $1.76. The stock has a market cap of $269.40 million, a PE ratio of -13.18 and a beta of 1.56. Cerus Co. has a 52-week low of $1.38 and a 52-week high of $2.54. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The business had revenue of $50.81 million for the quarter, compared to analyst estimates of $50.81 million. On average, equities research analysts forecast that Cerus Co. will post -0.08 EPS for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.

Institutional Investors Weigh In On Cerus

Hedge funds have recently bought and sold shares of the stock. Rockport Wealth LLC purchased a new stake in Cerus in the 4th quarter worth approximately $25,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Cerus in the 4th quarter worth approximately $25,000. Cibc World Markets Corp purchased a new stake in Cerus in the 4th quarter worth approximately $26,000. R Squared Ltd purchased a new stake in Cerus in the 4th quarter worth approximately $29,000. Finally, Virtu Financial LLC purchased a new stake in Cerus in the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.